Annovis Bio reported that the results of its Phase 2/3 study of buntanetap in mild‑to‑moderate Alzheimer’s disease were published in Nature NPJ Dementia. The randomized, double‑blind, placebo‑controlled trial enrolled 351 patients and evaluated 7.5 mg, 15 mg, and 30 mg doses over 12 weeks.
The publication confirms that buntanetap was safe and well‑tolerated across all dose levels, with no increase in adverse events among ApoE4 carriers and no safety signals when combined with approved symptomatic therapies. Statistically significant, dose‑dependent cognitive improvements were observed in pTau217‑positive patients with mild AD (MMSE 21–24), and the 30 mg dose produced consistent treatment effects across age, BMI, sex, ethnicity, ApoE4 status, and concomitant medication use.
Biomarker analyses showed reductions in neurotoxic proteins (TDP‑43, tau) and inflammatory markers (IL‑5, IL‑6, S100A12, IFN‑γ, IGF1R) as well as in neurofilament light chain, suggesting potential disease‑modifying activity. Similar trends were seen in plasma samples from patients with moderate AD, supporting the drug’s mechanism of action.
"The data reinforce what we have seen across multiple studies: buntanetap addresses the underlying pathology of AD with a safety profile that supports its use in a broad, genetically diverse patient population. The treatment effect we observed in biomarker‑confirmed early AD patients provides strong scientific rationale as we advance our drug candidate through a pivotal Phase 3 study," said Cheng Fang, Ph.D., Senior Vice President, Research & Development.
The positive Phase 2/3 results strengthen Annovis’s competitive position and provide a scientific foundation for the company’s ongoing Phase 3 trial, which is approximately 80 % enrolled and has received FDA protocol acceptance. The company’s recent $10 million offering and strong current ratio of 5.8 give it financial flexibility to support the expanded Phase 3 program and other pipeline assets, including a Parkinson’s disease indication that has also shown encouraging Phase 3 data.
Investors and analysts view the publication as a key milestone that validates the drug’s safety and efficacy profile, bolsters confidence in the Phase 3 program, and underscores Annovis’s potential to address an unmet need in Alzheimer’s disease.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.